TargetBeta
CDH6
cadherin 6 · Type II classical cadherins
3 programs in company-led studies act on CDH6, from 3 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| raludotatug deruxtecan | Merck | phase 3 | 1111 running | – | the company's pipeline |
| TJ102rule | Phrontline Biopharma | phase 2 | 11 running | – | the studies' text |
| Anti-CDH6 Antibody-drug Conjugate SIM0505rule | NextCure | phase 1 | 11 running | – | NCIt |
Conditions their studies are in
- Fallopian Tube Neoplasms, 2 programs
- Ovarian Neoplasms, 2 programs
- Carcinoma, Non-Small-Cell Lung, 1 program
- Carcinoma, Renal Cell, 1 program
- Lung Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 30, 2026raludotatug deruxtecan · Merck · phase 3 · NCT04707248
- Feb 2028Anti-CDH6 Antibody-drug Conjugate SIM0505 · NextCure · phase 1 · NCT06792552
- Sep 2029TJ102 · Phrontline Biopharma · phase 2 · NCT07778498
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.